Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.

Toosi BM, El Zawily A, Truitt L, Shannon M, Allonby O, Babu M, DeCoteau J, Mousseau D, Ali M, Freywald T, Gall A, Vizeacoumar FS, Kirzinger MW, Geyer CR, Anderson DH, Kim T, Welm AL, Siegel P, Vizeacoumar FJ, Kusalik A, Freywald A.

Oncogene. 2018 Apr 27. doi: 10.1038/s41388-018-0228-x. [Epub ahead of print]

PMID:
29700392
2.

Simulated microgravity inhibits cell focal adhesions leading to reduced melanoma cell proliferation and metastasis via FAK/RhoA-regulated mTORC1 and AMPK pathways.

Tan X, Xu A, Zhao T, Zhao Q, Zhang J, Fan C, Deng Y, Freywald A, Genth H, Xiang J.

Sci Rep. 2018 Feb 28;8(1):3769. doi: 10.1038/s41598-018-20459-1.

3.

Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.

Xie Y, Wu J, Xu A, Ahmeqd S, Sami A, Chibbar R, Freywald A, Zheng C, Xiang J.

Vaccine. 2018 Mar 7;36(11):1414-1422. doi: 10.1016/j.vaccine.2018.01.078. Epub 2018 Feb 5.

PMID:
29415817
4.

An integrated computational and experimental study uncovers FUT9 as a metabolic driver of colorectal cancer.

Auslander N, Cunningham CE, Toosi BM, McEwen EJ, Yizhak K, Vizeacoumar FS, Parameswaran S, Gonen N, Freywald T, Bhanumathy KK, Freywald A, Vizeacoumar FJ, Ruppin E.

Mol Syst Biol. 2017 Dec 1;13(12):956. doi: 10.15252/msb.20177739.

5.

The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment.

El Zawily A, McEwen E, Toosi B, Vizeacoumar FS, Freywald T, Vizeacoumar FJ, Freywald A.

Sci Rep. 2017 Nov 7;7(1):14767. doi: 10.1038/s41598-017-15200-3.

6.

CD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via naïve T-cell anergy.

Xu A, Freywald A, Xie Y, Li Z, Xiang J.

Immunotargets Ther. 2017 Jun 15;6:39-49. doi: 10.2147/ITT.S131662. eCollection 2017.

7.

CD40 agonist converting CTL exhaustion via the activation of the mTORC1 pathway enhances PD-1 antagonist action in rescuing exhausted CTLs in chronic infection.

Xu A, Wang R, Freywald A, Stewart K, Tikoo S, Xu J, Zheng C, Xiang J.

Biochem Biophys Res Commun. 2017 Mar 11;484(3):662-667. doi: 10.1016/j.bbrc.2017.01.172. Epub 2017 Jan 31.

PMID:
28153727
8.

Enhanced suppression of polyclonal CD8+25+ regulatory T cells via exosomal arming of antigen-specific peptide/MHC complexes.

Mu C, Zhang X, Wang L, Xu A, Ahmed KA, Pang X, Chibbar R, Freywald A, Huang J, Zhu Y, Xiang J.

J Leukoc Biol. 2017 May;101(5):1221-1231. doi: 10.1189/jlb.3A0716-295RR. Epub 2017 Jan 17.

PMID:
28096300
9.

Novel T-cell-based vaccines via arming polyclonal CD4+ T cells with antigen-specific exosomes.

Xu A, Freywald A, Xiang J.

Immunotherapy. 2016 Nov;8(11):1265-1269. No abstract available.

PMID:
27993084
10.

The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation.

El Zawily AM, Toosi BM, Freywald T, Indukuri VV, Vizeacoumar FJ, Leary SC, Freywald A.

Oncotarget. 2016 Nov 22;7(47):77865-77877. doi: 10.18632/oncotarget.12838.

11.

Therapeutic relevance of the protein phosphatase 2A in cancer.

Cunningham CE, Li S, Vizeacoumar FS, Bhanumathy KK, Lee JS, Parameswaran S, Furber L, Abuhussein O, Paul JM, McDonald M, Templeton SD, Shukla H, El Zawily AM, Boyd F, Alli N, Mousseau DD, Geyer R, Bonham K, Anderson DH, Yan J, Yu-Lee LY, Weaver BA, Uppalapati M, Ruppin E, Sablina A, Freywald A, Vizeacoumar FJ.

Oncotarget. 2016 Sep 20;7(38):61544-61561. doi: 10.18632/oncotarget.11399.

12.

Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.

Paul JM, Toosi B, Vizeacoumar FS, Bhanumathy KK, Li Y, Gerger C, El Zawily A, Freywald T, Anderson DH, Mousseau D, Kanthan R, Zhang Z, Vizeacoumar FJ, Freywald A.

Oncotarget. 2016 Aug 2;7(31):50027-50042. doi: 10.18632/oncotarget.10569.

13.

Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway.

Wang R, Xu A, Zhang X, Wu J, Freywald A, Xu J, Xiang J.

Cell Mol Immunol. 2017 Jun;14(6):529-545. doi: 10.1038/cmi.2016.23. Epub 2016 Jun 6.

14.

IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia.

Xu A, Bhanumathy KK, Wu J, Ye Z, Freywald A, Leary SC, Li R, Xiang J.

Cell Biosci. 2016 May 6;6:30. doi: 10.1186/s13578-016-0098-2. eCollection 2016.

15.

Simulated Microgravity Promotes Cell Apoptosis Through Suppressing Uev1A/TICAM/TRAF/NF-κB-Regulated Anti-Apoptosis and p53/PCNA- and ATM/ATR-Chk1/2-Controlled DNA-Damage Response Pathways.

Zhao T, Tang X, Umeshappa CS, Ma H, Gao H, Deng Y, Freywald A, Xiang J.

J Cell Biochem. 2016 Sep;117(9):2138-48. doi: 10.1002/jcb.25520. Epub 2016 Mar 8.

PMID:
26887372
16.

Spindle Checkpoint Factors Bub1 and Bub2 Promote DNA Double-Strand Break Repair by Nonhomologous End Joining.

Jessulat M, Malty RH, Nguyen-Tran DH, Deineko V, Aoki H, Vlasblom J, Omidi K, Jin K, Minic Z, Hooshyar M, Burnside D, Samanfar B, Phanse S, Freywald T, Prasad B, Zhang Z, Vizeacoumar F, Krogan NJ, Freywald A, Golshani A, Babu M.

Mol Cell Biol. 2015 Jul;35(14):2448-63. doi: 10.1128/MCB.00007-15. Epub 2015 May 11.

17.

N-(2,4)-dinitrophenyl-L-arginine Interacts with EphB4 and Functions as an EphB4 Kinase Modulator.

Kamstra RL, Freywald A, Floriano WB.

Chem Biol Drug Des. 2015 Oct;86(4):476-86. doi: 10.1111/cbdd.12510. Epub 2015 Feb 6.

PMID:
25581780
18.

Yeast mitochondrial protein-protein interactions reveal diverse complexes and disease-relevant functional relationships.

Jin K, Musso G, Vlasblom J, Jessulat M, Deineko V, Negroni J, Mosca R, Malty R, Nguyen-Tran DH, Aoki H, Minic Z, Freywald T, Phanse S, Xiang Q, Freywald A, Aloy P, Zhang Z, Babu M.

J Proteome Res. 2015 Feb 6;14(2):1220-37. doi: 10.1021/pr501148q. Epub 2015 Jan 20.

PMID:
25546499
19.

Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell.

Paul JM, Templeton SD, Baharani A, Freywald A, Vizeacoumar FJ.

Trends Mol Med. 2014 Dec;20(12):704-15. doi: 10.1016/j.molmed.2014.09.009. Epub 2014 Oct 22. Review.

PMID:
25446836
20.
21.

Ligand stimulation induces clathrin- and Rab5-dependent downregulation of the kinase-dead EphB6 receptor preceded by the disruption of EphB6-Hsp90 interaction.

Allonby O, El Zawily AM, Freywald T, Mousseau DD, Chlan J, Anderson D, Benmerah A, Sidhu V, Babu M, DeCoteau J, Freywald A.

Cell Signal. 2014 Dec;26(12):2645-57. doi: 10.1016/j.cellsig.2014.08.007. Epub 2014 Aug 23.

PMID:
25152371
22.

The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.

Satram-Maharaj T, Nyarko JN, Kuski K, Fehr K, Pennington PR, Truitt L, Freywald A, Lukong KE, Anderson DH, Mousseau DD.

Cell Signal. 2014 Dec;26(12):2621-32. doi: 10.1016/j.cellsig.2014.08.005. Epub 2014 Aug 22.

PMID:
25152370
23.

Th cells promote CTL survival and memory via acquired pMHC-I and endogenous IL-2 and CD40L signaling and by modulating apoptosis-controlling pathways.

Umeshappa CS, Xie Y, Xu S, Nanjundappa RH, Freywald A, Deng Y, Ma H, Xiang J.

PLoS One. 2013 Jun 13;8(6):e64787. doi: 10.1371/journal.pone.0064787. Print 2013.

24.
25.

CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination.

Sokke Umeshappa C, Hebbandi Nanjundappa R, Xie Y, Freywald A, Deng Y, Ma H, Xiang J.

PLoS One. 2012;7(10):e47004. doi: 10.1371/journal.pone.0047004. Epub 2012 Oct 5.

26.

A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.

Xie Y, Wang L, Freywald A, Qureshi M, Chen Y, Xiang J.

Cell Mol Immunol. 2013 Jan;10(1):72-7. doi: 10.1038/cmi.2012.37. Epub 2012 Oct 8.

27.

CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene.

Ankathatti Munegowda M, Xu S, Freywald A, Xiang J.

Mol Immunol. 2012 Jun;51(2):143-9. doi: 10.1016/j.molimm.2012.02.120. Epub 2012 Mar 17.

PMID:
22424785
28.

EphB receptors trigger Akt activation and suppress Fas receptor-induced apoptosis in malignant T lymphocytes.

Maddigan A, Truitt L, Arsenault R, Freywald T, Allonby O, Dean J, Narendran A, Xiang J, Weng A, Napper S, Freywald A.

J Immunol. 2011 Dec 1;187(11):5983-94. doi: 10.4049/jimmunol.1003482. Epub 2011 Oct 28.

29.

A distinct role of CD4+ Th17- and Th17-stimulated CD8+ CTL in the pathogenesis of type 1 diabetes and experimental autoimmune encephalomyelitis.

Ankathatti Munegowda M, Deng Y, Chibbar R, Xu Q, Freywald A, Mulligan SJ, van Drunen Littel-van den Hurk S, Sun D, Xiong S, Xiang J.

J Clin Immunol. 2011 Oct;31(5):811-26. doi: 10.1007/s10875-011-9549-z. Epub 2011 Jun 15.

30.

Dancing with the dead: Eph receptors and their kinase-null partners.

Truitt L, Freywald A.

Biochem Cell Biol. 2011 Apr;89(2):115-29. doi: 10.1139/o10-145. Review.

PMID:
21455264
31.

The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells.

Truitt L, Freywald T, DeCoteau J, Sharfe N, Freywald A.

Cancer Res. 2010 Feb 1;70(3):1141-53. doi: 10.1158/0008-5472.CAN-09-1710. Epub 2010 Jan 19.

32.

In human leukemia cells ephrin-B-induced invasive activity is supported by Lck and is associated with reassembling of lipid raft signaling complexes.

Jiang G, Freywald T, Webster J, Kozan D, Geyer R, DeCoteau J, Narendran A, Freywald A.

Mol Cancer Res. 2008 Feb;6(2):291-305. doi: 10.1158/1541-7786.MCR-07-0047.

33.

EphA and ephrin-A proteins regulate integrin-mediated T lymphocyte interactions.

Sharfe N, Nikolic M, Cimpeon L, Van De Kratts A, Freywald A, Roifman CM.

Mol Immunol. 2008 Mar;45(5):1208-20. Epub 2007 Nov 5.

PMID:
17980912
34.

EphA receptors inhibit anti-CD3-induced apoptosis in thymocytes.

Freywald A, Sharfe N, Miller CD, Rashotte C, Roifman CM.

J Immunol. 2006 Apr 1;176(7):4066-74.

35.

Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor.

Grunberger T, Demin P, Rounova O, Sharfe N, Cimpean L, Dadi H, Freywald A, Estrov Z, Roifman CM.

Blood. 2003 Dec 1;102(12):4153-8. Epub 2003 Jul 24.

36.

Ephrin-A1 induces c-Cbl phosphorylation and EphA receptor down-regulation in T cells.

Sharfe N, Freywald A, Toro A, Roifman CM.

J Immunol. 2003 Jun 15;170(12):6024-32.

37.

The EphB6 receptor inhibits JNK activation in T lymphocytes and modulates T cell receptor-mediated responses.

Freywald A, Sharfe N, Rashotte C, Grunberger T, Roifman CM.

J Biol Chem. 2003 Mar 21;278(12):10150-6. Epub 2003 Jan 6.

38.

Ephrin stimulation modulates T cell chemotaxis.

Sharfe N, Freywald A, Toro A, Dadi H, Roifman C.

Eur J Immunol. 2002 Dec;32(12):3745-55.

39.

The kinase-null EphB6 receptor undergoes transphosphorylation in a complex with EphB1.

Freywald A, Sharfe N, Roifman CM.

J Biol Chem. 2002 Feb 8;277(6):3823-8. Epub 2001 Nov 16.

40.

Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins.

Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y.

Oncogene. 1996 Mar 7;12(5):1117-25.

PMID:
8649804
41.

Proteins separated from human IgG molecules.

Nezlin R, Freywald A, Oppermann M.

Mol Immunol. 1993 Jul;30(10):935-40.

PMID:
8341284
42.

Complexes of IgG molecules and C3a and C4a complement components in human serum.

Nezlin R, Freywald A.

Eur J Immunol. 1992 Jul;22(7):1955-7.

PMID:
1623933

Supplemental Content

Loading ...
Support Center